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Abstract
Objective: The goal of the study was to analyze the histological and clinical trends in lung carcinoma and their influence upon the
preoperative evaluation, surgical procedures and survival. Methods: We retrospectively reviewed the charts of 1079 consecutive patients
who underwent surgery for primary lung carcinoma between 1977 and 1996 in our institution. Patients were divided into five equal 4-year
periods according to the year of surgery (1977–1980; 1981–1984; 1985–1988; 1989–1992; 1993–1996). Results: Between 1977–1980
and 1993–1996, the incidence of squamous cell carcinoma significantly declined, whereas the incidence of adenocarcinoma and bronch-
ioloalveolar carcinoma increased. During the same period, the proportion of squamous cell carcinoma visualized at bronchoscopy and the
rate of preoperative histological diagnosis significantly decreased. An increasing proportion of lobectomy and less extended resection was
associated with an increasing number of patients with stage I carcinoma. Meanwhile, the operative mortality significantly declined from 9
to 4% and the 5-year survival improved from 25 up to 40%. Conclusion: Over the last two decades, the shift in histological distribution was
associated with an increasing proportion of patients with stage I disease, a lower operative mortality and a better 5-year survival. Ó 1999
Elsevier Science B.V. All rights reserved.
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1. Introduction
Although a shift in the histologic distribution of pri-
mary lung carcinoma has been reported, few studies
have analyzed the trends in operative strategy and survival
after lung resection [1,2]. Therefore, we retrospectively
reviewed all patients who underwent surgery for pri-
mary lung carcinoma over the last 20 years at the University
Hospital of Geneva, and we analyzed the histological
and clinical changes in lung cancer and their influence
upon preoperative evaluation, surgical procedures and sur-
vival.
2. Materials and methods
Between January 1, 1977 and December 31, 1996, a total
of 4245 patients were identified with the diagnosis of pri-
mary lung carcinoma in Geneva according to the regional
cancer register. Among these patients, 1265 (29.8%) under-
went surgery, 1079 (85.6%) in our institution and 186
(14.4%) in other medical centres.
The charts from all patients operated in our institution
were retrospectively reviewed and data on patient’s age,
bronchoscopic findings, tobacco use in pack-year unit
(number of tobacco-pack smoked each day times the
number of years of smoking), type of surgical procedures,
histology and stage of disease were extracted. Patients
were subsequently grouped according to the year of
surgery into five equal 4-year periods (1977–1980;
1981–1984; 1985–1988; 1989–1992; 1993–1996) (Table
1).
Preoperative diagnostic evaluation included chest X-ray,
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bronchoscopy, liver function testing, and liver ultrasonogra-
phy. Since 1984, computed tomographic (CT) of the thorax
and upper abdomen was also included in the standard diag-
nostic work-up. When mediastinal lymph nodes were
enlarged on CT (larger than 15 mm in the largest diameter),
a mediastinoscopy was performed in order to exclude the
patients with N3 disease from surgery. The type of resection
was primarily dictated by the local extent of the tumour and
secondarily, by the cardiorespiratory function. With regard
to pathological staging of the tumour, patients underwent
selective sampling of suspicious mediastinal lymph nodes
prior to 1992, and systematic mediastinal dissection there-
after. Histologic typ-ing was conducted according to the
World Health Organization [3]. Tumour extent was
reviewed and determined according to the revised TNM
classification for all patients [4].
Adjuvant chemoradiotherapy was administrated to all
patients with mediastinal lymph nodes involvement. In
addition, radiotherapy was used when the resection was
not microscopically complete and, lately, chemotherapy
has been randomly assigned to patients with N1 involve-
ment.
Information on follow-up was obtained from hosp-
ital charts, phone calls to general practitioners, and re-
view of the regional cancer registry. The cut-off date for
the evaluation was at the end of the 5th year following sur-
gery and January 1, 1998 for the patients operated after
January 1, 1993. Eighty-seven patients (8%) were lost to
follow-up.
2.1. Statistical analysis
Differences in distribution on time-variables were ana-
lyzed by Friedman ANOVA-test and chi-square test for
trend. Operative mortality included patients deceased
within 30 days of surgery and any later deaths occurring
during the initial postoperative hospital stay. The 5-year
survival, including the operative mortality, was analyzed
by the Kaplan–Meier method, and the evaluation of the
differences was conducted by the log-rank test for trend.
Differences with P-values no greater than 0.05, were
regarded as statistically significant.
3. Results
There were 877 males and 202 females, aged 61.2 – 9.2
years (mean – SD, range 27 to 89 years) and 61.7 – 10.1
years (range 34 to 82 years), respectively. There were 613
patients with squamous cell carcinoma (57%), 327 with
adenocarcinoma (30.3%), 47 with large cell carcinoma
(4.3%), 44 with bronchioloalveolar carcinoma (4%), 33
with small cell carcinoma (3%), and 15 with undifferen-
tiated carcinoma (1.4%).
3.1. Trend in histology (Fig. 1)
The incidence of squamous cell carcinoma significantly
declined, whereas, that of adenocarcinoma and bronchio-
loalveolar carcinoma increased. Although this histological
shift was observed in both genders, the trend was more
significant in females and tended to level off over the last
8 years of our study.
3.2. Trend in smoking habit (Fig. 2)
While the proportion of heavy smokers (.40 pack-year)
remained constant at a rate of 50% or higher in males, in
females, the incidence of heavy smoker increased signifi-
cantly from 12% in 1977–1980 up to 40% in 1993–1996.
Interestingly, 32% of the patients with bronchioloalveolar
Fig. 1. Trend in histological types among males and females operated
between 1977 and 1996 (*chi-square test for trend).
Table 1
Demographic and characteristic patterns of patients operated for primary lung carcinoma at the University Hospital of Geneva between 1977 and 1996
1977–1980 1981–1984 1985–1988 1989–1992 1993–1996
Patients diagnosed with PLC in Geneva 810 855 881 860 840
Patients undergoing surgery in our
Institution (%)
224 (28) 236 (28) 208 (24) 188 (22) 223 (27)
Mean age of patients operated
(mean year – SD)
59.6 – 8.9 60.3 – 8.9 60.7 – 9.1 61.2 – 9.3 64.6 – 9.9
Sex ratio among patients operated
(male:female)
7.9:1 6.6:1 3.7:1 3.1:1 2.9:1
PLC, primary lung carcinoma.
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carcinoma had never smocked, whereas the rate of non-
smoker among other carcinomas ranged from 2% in squa-
mous cell carcinoma to 11% in adenocarcinoma.
3.3. Trend in bronchoscopic findings (Fig. 3)
Bronchoscopy was performed preoperatively in 90–98%
of the patients with squamous cell carcinoma and in 80–
90% of the patients with adenocarcinoma. While in squa-
mous cell carcinoma, the tumour was usually visualized and
a histological diagnosis obtained, this performance progres-
sively decreased over the last 20 years. In contrast, broncho-
scopy has remained negative in most patients with
adenocarcinoma. Concomitantly, a transthoracic fine needle
biopsy was performed more frequently in patients with ade-
nocarcinoma than in those with squamous cell carcinoma.
3.4. Trend in surgical procedures and stage of disease
(Table 2)
The proportion of patients with a tumour of stage 1
increased over time. Meanwhile, the number of lobectomy
and less extended resection increased, whereas, the rate of
larger resection (pneumonectomy and bilobectomy) and
exploratory thoracotomy significantly declined.
3.5. Trend in operative mortality and 5-year survival
(Table 2 and Fig. 4)
While the operative mortality significantly decreased
over the last 20 years, the 5-year survival increased.
Although an improvement was observed between each 5-
year period, the turning point of survival benefit was situ-
ated between the first two and the last three periods of our
study (Fig. 4). No differences in the operative mortality and
long-term survival was observed between squamous cell
carcinoma, adenocarcinoma and the other non-small cell
carcinoma. After hospital discharge, lung carcinoma (recur-
rence, metastasis) was the main cause of death in 79% of the
cases (n = 580), 12% died of another cause (n = 87), and
the cause remained unknown in 9% (n = 65). Survival was
similar in patients who died from their lung carcinoma (34%
at 5 years) and in those who died from other diseases (31%
at 5 years).
4. Discussion
Over the last 20 years, the proportion of adenocarcinoma
and bronchioloalveolar carcinoma significantly increased,
whereas the rate of squamous cell carcinoma concomitantly
decreased. This histological shift had been previously
reported in the US in the 1970s [5,6], and was more recently
observed in Europe and Asia [7–10]. Hence, since the Uni-
versity Hospital of Geneva is the single regional referring
center, our findings may be considered as a good mirror of
the histological trends among the overall population of Gen-
eva.
In accordance with some authors [11,12], but in contrast
to previous Swiss studies [8], in our series, the histological
shift was more pronounced in females than in males.
Indeed, in the last decade, adenocarcinoma predominated
in females, whereas squamous cell carcinoma were still
diagnosed in the majority of males. This phenomenon
could be related to changes in female smoking habits,
since heavy smokers largely increased among females in
our series, whereas tobacco use remained relatively stable
in males. Furthermore, since the beginning of the 1990s, the
proportion of heavy smokers and the rate of adenocarci-
noma among females concomitantly levelled off in our
institution.
The introduction of filter cigarettes could also have con-
tributed to the shift in lung carcinoma cell type. While large
particles are selectively removed by cigarette filters, small
particles are not and may, thus, promote carcinogenesis and
increase the development of adenocarcinoma [6,13]. In
addition, the deeper puffs taken because of filter cigarettes
may have resulted in the occurrence of tumours located
more peripherally in the lung [14]. We found a decreasing
number of squamous cell carcinoma visualized at broncho-
scopy, and Quinn et al. [15] observed an increasing rate of
squamous cell carcinoma in the periphery of the lung on
chest X-ray.
Although the mean age of patients undergoing surgery
Fig. 2. Smoking habit in males and females operated between 1977 and
1996 (*chi-square test for trend; **pack-year = the number of tobacco-
packs smoked per day · the number of years smoking).
Fig. 3. Histologic diagnosis prior to surgery by bronchoscopy and fine
needle biopsy (*histology and/or cytology positive/**within a bronchus).
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increased, the overall operative mortality significantly
decreased. This finding was likely due to the lowering in
the proportion of bilobectomy and pneumonectomy ob-
served during our study [16]. In addition, better preopera-
tive cardiopulmonary evaluation and postoperative manage-
ment were likely to contributed to the progressive reduction
in the operative mortality over the last 20 years.
The 5-year survival rate, significantly improved through-
out the period studied. This improvement was associated
with a decreasing rate of operation-related death, a decreas-
ing proportion of exploratory thoracotomy and an increas-
ing incidence of stage I carcinoma. Although this
improvement was observed between each 5-year period, it
seems to have predominated between the first two and the
last three periods. Some of these changes may be explained
by the introduction of chest CT in the early 1980s and its
systematic application for clinical staging since 1984.
Indeed, better preoperative evaluation of local tumour
extension and the status of mediastinal lymph nodes invol-
vement, certainly helped to improve the patient’s selection
and thus, survival by excluding the patients with advanced-
stage carcinoma. Postoperative chemoradiotherapy in
patients with stage III disease, and more recently che-
motherapy in patients with stage II disease, may have con-
tributed to increase the long-term survival. However, due to
the variety of drugs and type of radiation used over the last
two decades, their influence could not be assessed in this
study
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Appendix A Conference discussion
Mr K. Moghissi (East Yorkshire, UK): I have had an interest for some
time about the resectability rate in Europe. I have found that for the last 40
years it has not moved, and is in the region of 15%. In the UK, for instance,
it has been 10–12%. I would like to ask you a question about the resect-
ability rate in the canton of Geneva, as I know that you collect data from
there; also a clarification both in your expose and in the abstract. You are
dealing with 1079 patients, of which 24% were primary lung cancer. If it is
so, were the rest secondary lung cancer? So two questions. Why so many
secondary lung cancer, if they are secondary lung cancers, or is there a
mistake here? Secondly, what is the resectability rate.
Dr de Perrot: The first question was about resectability rate. We
observed an increased resectability rate from 90 to 95% at the beginning
of the 1980s with the introduction of the computer tomography scanner in
Geneva. Regarding the second question, we called primary lung carcino-
mas, all non-small-cell lung carcinomas and small-cell lung carcinomas, as
opposed to secondary carcinomas which were metastasis and carcinoid
tumors, as well as sarcomas which were not included in the study.
Mr P. Goldstraw (London, UK): Surely if we are to know whether these
changes are merely those of changes in surgical attitude or whether they’re
truly epidemiological changes, we need to know the denominator. Have
you got any evidence that the proportion of patients that you have operated
on has not changed? Have you any evidence that the population character-
istics of your non-operated cases are the same as your operated cases?
Dr de Perrot: We have looked at that and the proportion is the same. It
varies between 22 and 28%, according to the Geneva cancer history which
gives the total amount of patients diagnosed in Geneva. However, survival
curves may have increased because lung cancers are diagnosed earlier and
patient selection is better. Therefore, the 5-year survival would have been
increasing because the type of patients have changed but not because the
real 5-year survival has increased.
Dr A. End (Vienna, Austria): We know the surgeon to be a prognostic
factor. Did you look if the variable, ‘surgeon’, influenced the outcome at
your institution?
Dr de Perrot: We have not looked at that, but certainly the quality and
expertise of the surgeon plays a role in the operative mortality.
Dr T.F. Molnar (Pecs, Hungary): Recently, more and more pathologi-
cal reports come back to me with the diagnosis adenosquamous carcinoma
or mixed-type carcinoma. I am troubled as how to decode this message,
maybe it’s due to the immunohistochemistry or something else. Do you
have similar experiences in your institution with the increasing number of
these so-called mixed-type cancers?
Dr de Perrot: Yes, the mixed type have been increasing, but we did not
have many of them in our institution, so we don’t have so much experience
with them.
.
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